5-ALA FLUORESCENCE-GUIDED
BRAIN TUMOUR SURGERY
A drink taken the morning of surgery that makes glioma cells glow pink under the operating microscope — the most widely adopted advance in high-grade glioma surgery of the last two decades.
analyticsAt a Glance
- check_circle5-ALA (Gliolan) is swallowed 3 hours before surgery — no injection required
- check_circleMalignant glioma cells metabolise 5-ALA into fluorescent protoporphyrin IX (PpIX), which glows pink under 405 nm violet light
- check_circlePhase III RCT: 5-ALA increased complete resection from 36% to 65% versus white light microsurgery
- check_circleEMA-approved since 2007; available at neurosurgery centres in China, India, Europe, and the USA via CancerFax
What Is 5-ALA and How Does It Make Tumours Glow?
5-aminolevulinic acid (5-ALA, brand name Gliolan) is a naturally occurring amino acid precursor to haem — the oxygen-carrying component of haemoglobin. When given orally in a higher pharmacological dose before surgery, it is preferentially taken up by malignant brain tumour cells (especially GBM and grade 3 glioma), which metabolise it into fluorescent protoporphyrin IX (PpIX).
“Normal brain tissue cannot see the tumour edge — but 5-ALA makes it glow. It is one of the simplest and most impactful tools ever introduced to neuro-oncology surgery.”
The Fluorescence Mechanism
Malignant glioma cells have dysregulated haem synthesis and accumulate PpIX when loaded with 5-ALA. Under 405 nm violet light through the surgical microscope, PpIX emits a vivid pink-red fluorescence visible against the blue-grey of normal brain tissue.
Why Normal Brain Doesn't Glow
Non-malignant brain tissue either does not take up 5-ALA sufficiently or does not accumulate PpIX to a visible fluorescent level. This creates the visual contrast that guides the surgeon — though low-grade glioma and reactive changes can produce faint fluorescence.
Key Clinical Numbers for 5-ALA Surgery
The pivotal ALA-Glioma Study Group phase III RCT remains the strongest evidence base — but decades of clinical use have further solidified these benchmarks.
- 65% vs 36%Complete resection rate: 5-ALA vs white light (phase III RCT)The pivotal Stummer et al RCT (Lancet Oncology 2006) showed complete resection of contrast-enhancing tumour in 65% of 5-ALA patients vs 36% with white light — nearly doubling GTR rates.
- +5.8 wksProgression-free survival improvement at 6 months6-month PFS rate was 41% with 5-ALA vs 21% with white light in the phase III trial — a clinically meaningful delay in progression despite no significant change in overall survival.
- EMA 2007Regulatory approval year (Europe)5-ALA (Gliolan) received European Medicines Agency approval in 2007 for visualisation of malignant tissue during surgery for malignant glioma — one of the first oncology surgical agents to receive regulatory approval.
How 5-ALA Fluorescence Surgery Works: The Patient Experience
The 5-ALA protocol is straightforward from the patient's perspective — a drink in the morning, surgery as usual, but with a different coloured light under the microscope.
- 1
Fasting and Pre-operative Preparation
Standard neurosurgical pre-operative preparation. Patient fasts from midnight. 5-ALA is dissolved in water and must be taken at a precise time relative to surgery.
- 2
5-ALA Oral Administration
Patient drinks 5-ALA solution (20 mg/kg body weight dissolved in water) 3 hours before the planned anaesthetic induction. The drink has a slightly bitter taste but is generally well tolerated.
- 3
Standard Craniotomy Under General Anaesthesia
Surgery proceeds as a standard craniotomy. The key difference is the surgical microscope — equipped with a 405 nm violet light filter and appropriate emission filters to visualise PpIX fluorescence.
- 4
Resection Under Fluorescence Guidance
The surgeon switches between white light (standard tissue visualisation) and violet light (fluorescence mode) to identify tumour margins, satellite deposits, and infiltrating tumour at the resection edge.
- 5
Post-operative Light Precautions
5-ALA causes temporary photosensitisation of the skin and eyes. Patient must avoid bright light exposure for 24 hours post-surgery — a simple but important safety measure communicated pre-operatively.
Which Brain Tumours Benefit from 5-ALA?
5-ALA fluorescence is most reliable in high-grade gliomas — the more malignant the tumour, the more intense and reliable the fluorescence signal.
| Tumour Type | Fluorescence Reliability | Clinical Utility |
|---|---|---|
| Glioblastoma (GBM) | Strong, intense pink fluorescence in >90% of cases | Primary indication — phase III RCT evidence; standard of care at most centres |
| Grade 3 anaplastic astrocytoma | Reliable fluorescence in majority of cases | Well-established utility; included in EMA approval scope |
| Grade 3 oligodendroglioma | Moderate fluorescence — less reliable than GBM | Useful adjunct; interpret with caution given lower PpIX accumulation |
| Grade 2 low-grade glioma (IDH-mutant) | Weak or absent fluorescence in most cases | Limited utility; non-enhancing low-grade tumours accumulate insufficient PpIX |
| Brain metastases | Variable — some carcinoma histologies fluoresce | Investigational; not standard of care for brain metastases |
| Meningioma | Moderate fluorescence reported in some series | Not routinely used; 5-ALA not approved for meningioma |
5-ALA Fluorescence vs Standard White Light Microsurgery
Both approaches use the surgical microscope — but 5-ALA adds a second mode of tumour detection that addresses the fundamental limitation of visual tumour identification under white light.
5-ALA Fluorescence-Guided Surgery
- Visualises tumour cells invisible to the naked eyePpIX fluorescence reveals tumour tissue at the resection margin that appears identical to normal brain under white light — this is the core clinical value.
- Nearly doubles GTR rates in phase III RCTComplete resection of contrast-enhancing tumour increased from 36% to 65% with 5-ALA — the largest single-technology improvement in GBM surgical outcomes reported in an RCT.
- Minimal patient burden5-ALA is taken orally 3 hours before surgery — no additional procedure, no MRI scanner required, no significant side effects beyond 24-hour photosensitivity.
Standard White Light Microsurgery
- Relies on tissue appearance aloneTumour borders in high-grade glioma are infiltrative and not visually distinct from oedematous or reactive brain — the surgeon's judgement of the tumour edge is inherently imprecise.
- Higher rate of residual tumour at closurePhase III data confirms that standard white light surgery leaves residual contrast-enhancing tumour in 64% of GBM cases — a finding that directly impacts PFS and OS.
- Standard at most centres without 5-ALA infrastructureWhite light microsurgery requires no specialised equipment or drug preparation — it remains standard at centres that have not yet adopted 5-ALA.
Frequently Asked Questions
Common questions from patients and families exploring 5-ALA fluorescence-guided surgery.
About 5-ALA Surgery
Is 5-ALA approved outside Europe?
5-ALA (Gliolan) is EMA-approved (Europe, 2007) and FDA-approved in the USA under the brand name Gleolan (2017). In China and India, the drug is used at specialist centres — availability varies. CancerFax can confirm which centres in your preferred country have access to 5-ALA for fluorescence-guided surgery.
Can 5-ALA be used alongside intraoperative MRI?
Yes — and increasingly is. iMRI and 5-ALA provide complementary information: 5-ALA guides the surgeon's visual resection in real time, while iMRI assesses global residual tumour after the surgeon believes resection is complete. Combined use offers the most complete approach to maximising safe resection in GBM.
Are there side effects from 5-ALA?
5-ALA is generally well tolerated. The main precaution is photosensitisation: the skin and eyes become sensitive to sunlight for 24 hours, and patients must avoid bright light exposure during this period. Mild nausea may occur. Transient elevation of liver enzymes is occasionally seen but rarely clinically significant.
Does 5-ALA improve overall survival in GBM?
The phase III RCT showed improved 6-month PFS but did not demonstrate a statistically significant overall survival benefit — likely due to the trial's short follow-up and early crossover. However, numerous retrospective studies and meta-analyses show that greater extent of resection (which 5-ALA achieves) is associated with longer OS in GBM — making 5-ALA's indirect survival benefit clinically plausible and widely accepted.
More from the Brain Tumour Treatment Resource Library
Explore related guides on neurosurgical techniques, imaging-guided resection, and brain tumour access.
- ↑ Brain Tumour Treatment — Complete Guide
- Awake Craniotomy: What It Involves, Who Needs It, and Which Centres Perform It
- Intraoperative MRI for Brain Tumour Surgery
- Meningioma Treatment: Surgery, Gamma Knife, and Observation
- Medulloblastoma in Children: Molecular Subgroups, Treatment, and Outcomes
- Gamma Knife Radiosurgery for Brain Tumours: A Patient Guide
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Find a 5-ALA Fluorescence-Guided Surgery Centre
CancerFax can identify neurosurgery centres equipped with 5-ALA (Gliolan) and violet-light microscopes — and facilitate the referral process for international patients seeking fluorescence-guided glioma surgery.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified neurosurgeon before making treatment decisions.